Minhai_COVID-19_vaccine

Minhai COVID-19 vaccine

Minhai COVID-19 vaccine

Vaccine against COVID-19

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Quick Facts Vaccine description, Target ...

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]

In September, KCONVAC started phase II trials with 480 participants in China.[5]

Authorizations

Quick Facts
See also: List of COVID-19 vaccine authorizations § Minhai

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]

References

  1. [1]
    Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov
  2. [2]
    Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov
  3. [3]
    Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov
  4. [4]
    Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
  5. [5]
    Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
  6. [6]
    "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 20 May 2021.
Scholia has a profile for Minhai COVID-19 vaccine (Q106522079).


Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Minhai_COVID-19_vaccine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.